Partial
Mostly Aligned
Patient Risk:
Low
Summary
The AI-derived claims largely align with the labeling for indication, mechanism, pharmacodynamics, safety signals, and common adverse reactions. However, there are substantial omissions and some weight-management assertions not supported by the Ozempic label. The evaluation would be improved by explicitly addressing contraindications/boxed warnings, pregnancy/pediatric guidance, detailed dosing and administration, and clarifying that weight-management indications for obesity are not applicable to Ozempic (Wegovy is the approved obesity product).
Category Scores
MonitoringRecommendations
70
Accurate Statements
Ozempic is indicated for the treatment of type 2 diabetes.
1
Ozempic slows gastric emptying.
12.2
Ozempic slows gastric emptying and modulates insulin and glucagon in a glucose-dependent manner.
12.1
GLP-1 receptor agonist mechanism includes glucose-dependent insulin secretion and glucagon suppression.
12.1
Ozempic is marketed by Novo Nordisk.
17
Common side effects of Ozempic include nausea, vomiting, diarrhea, and injection-site reactions.
6.1
Rare but serious side effects include acute kidney injury, pancreatitis, and medullary thyroid carcinoma.
5.6, 5.2, 4, 5.1
Patients should be monitored closely while taking Ozempic and report any symptoms to their healthcare provider.
1
Ozempic is approved in the United States for the treatment of type 2 diabetes.
1
Unsupported Statements
Ozempic reduces appetite.
Not explicitly stated as a labeled claim in the provided sections.
Ozempic increases feelings of fullness.
Not explicitly stated as a labeled claim in the provided sections.
Semaglutide led to an average weight loss of 11.2% over 68 weeks in a trial involving over 3,200 participants.
Weight-loss trial figures are not presented as labeled indications in the Ozempic labeling.
In that trial, the placebo group experienced an average weight loss of 2.3%.
Not presented as a labeled claim in the Ozempic labeling provided.
Another study showed semaglutide users losing an average of 10.3% of their initial body weight over 20 weeks.
Not presented as a labeled claim in the Ozempic labeling provided.
Semaglutide was more effective than liraglutide (Saxenda) in promoting weight loss in a head-to-head trial.
Not presented as a labeled claim in the Ozempic labeling provided.
55.6% of semaglutide-treated participants achieved a 10% or greater weight loss compared to 35.8% of those on liraglutide.
Not presented as a labeled claim in the Ozempic labeling provided.
Novo Nordisk has patent protection for Ozempic in the United States until 2035.
Patent status is not a labeled claim in the provided Ozempic labeling.
As the patent expires, generic versions of Ozempic will likely become available, potentially increasing accessibility and affordability for patients.
Not a labeled claim; relates to market/patent dynamics outside labeling.
Its use for weight loss in the absence of diabetes remains an off-label indication.
Labeling does not authorize weight-loss use for Ozempic; weight-management indications are not part of Ozempic labeling.
Contradictions
Low
AI Statement
Label Reference
Important Omissions
Contraindications and boxed warnings for thyroid C-cell tumors (including MEN2) are not explicitly stated in the claims but are critical safety elements; ensure they are communicated.
Importance:
High
Pregnancy risk and Use in Pregnancy guidance (safety during pregnancy and lactation) is not addressed in the claims; provide explicit guidance from the label.
Importance:
High
Pediatric safety and pediatric use guidance (if applicable) is not addressed; verify pediatric usage guidelines.
Importance:
Moderate
Dosing safety: initiation and titration schedules to mitigate GI adverse events are not discussed in the claims.
Importance:
Moderate
Weight-management labeling for obesity is not applicable to Ozempic; clarify Wegovy's separate indication rather than implying Ozempic has weight-management approval.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Label-supported safety signals (pancreatitis, kidney injury, thyroid cancer risk) are acknowledged; however, several high-risk areas (contraindications in MEN2/MTC and pregnancy/pediatric guidance) are inadequately covered by the claims.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Weight-management weight-loss claims not supported by labeling; incomplete coverage of contraindications/boxed warnings and population-specific guidance.
Suggested Improvement
Explicitly map claims to label sections: clearly distinguish Wegovy vs Ozempic weight-management indications; include boxed warnings and contraindications (thyroid C-cell tumors; MEN2) from sections 4 and 5.1; add Use in Specific Populations (8.1, 8.3, 8.4) guidance; provide detailed dosing and initiation/titration details from section 2; verify storage/handling if relevant; ensure all weight-loss/obesity-related claims are removed or clearly labeled as non-Ozempic indications.